『Novo Nordisk: Huge Demand, Harder Profits | EP024』のカバーアート

Novo Nordisk: Huge Demand, Harder Profits | EP024

Novo Nordisk: Huge Demand, Harder Profits | EP024

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Huge demand. A harder profit equation.More patients do not automatically mean stronger shareholder returns. Novo Nordisk must turn expanding access and manufacturing capacity into earnings and cash while prices, competition and research costs press in.This episode follows Novo Nordisk’s ordinary B share, NOV.XETRA/EUR (ISIN DK0062498333). The reference is €34.80, the provider daily close dated 16 October 2026, refreshed on 18 October. The database updated at 21:16 Dubai on 16 October; that is an update time, not a supplied trade minute. Copenhagen’s DKK share quote and the NYSE ADR are separate references.What Novo sellsNovo Nordisk is a Danish pharmaceutical company supplying diabetes, obesity and rare-disease medicines, including Ozempic, Wegovy and insulin products. Wegovy now includes injectable and marketed oral products; the US pill launch was in January 2026. Patients, prescribers, insurers and public health systems shape access and realized prices. Clinical research and manufacturing remain central costs.Four financial findings* Earnings: H1 reported sales of DKK175.3bn and operating profit of DKK86.7bn include a DKK26.8bn noncash US340B rebate provision reversal. Adjusted sales were DKK148.6bn and adjusted operating profit DKK66.2bn; each grew 2% at constant exchange rates. Q2 also included DKK6.3bn of noncash pipeline impairments. Removing an accounting item does not erase its economic significance.* Margins: H1 adjusted operating margin was 44.6%. Adjusted gross margin fell to 79.3% from 83.1%, with lower prices, capacity-agreement changes and FX partly offset by productivity and product mix.* Balance sheet: June company-defined net debt was DKK86.5bn, excluding lease liabilities; cash at bank was DKK44.5bn. Cash generation, debt, research, investment and distributions must be considered together.* Investment: H1 operating cash flow of DKK79.3bn less PP&E purchases of DKK24.0bn produced DKK55.3bn of company-defined free cash flow. Payment timing and expense phasing helped. This definition changed in 2026, with comparatives restated. Annual guidance is around DKK55bn PP&E spending and DKK45–55bn free cash flow; doubling the half-year cash figure would misrepresent the outlook.The 2026 adjusted sales and operating-profit growth outlook is −6% to 0% at constant exchange rates. September Capital Markets Day describes lower future capex intensity and broadly stable adjusted operating margins by 2030 as ambitions, not achieved results or guaranteed guidance. No freshly validated normalized P/E is supplied here.Fixed-date price scenarios from €34.80The September research endpoints remain 18 September 2027 and 18 September 2031—about 11 months and 4 years 11 months from this episode. Returns below are cumulative price changes, excluding dividends. These are conditional scenarios, not achieved returns or calibrated probabilities.Evidence-weighted base: 18 Sep 2027 €43.81 (+25.9% price); 18 Sep 2031 €69.60 (+100.0% price).Separate simple-averaged bull: 18 Sep 2027 €52.53 (+50.9% price); 18 Sep 2031 €88.72 (+154.9% price).Separate simple-averaged middle: 18 Sep 2027 €44.72 (+28.5% price); 18 Sep 2031 €74.09 (+112.9% price).Separate simple-averaged bear: 18 Sep 2027 €37.02 (+6.4% price); 18 Sep 2031 €48.43 (+39.2% price).The evidence-weighted base aggregates research forecasts; its weights are not calibrated outcome probabilities. The public averaged table uses a different aggregation from the evidence-weighted base. Its displayed endpoint prices are rounded; its returns above are recalculated from those displayed prices. A positive modeled bear is not a loss floor. Volume, pricing, clinical outcomes and capacity returns can develop outside these assumptions.Dividend cash: amounts, timing and FXDividends are normally unequal payments twice yearly. The latest interim was DKK3.75 per ordinary share, with a payment date of 18 August 2026; the previous final of DKK7.95 was paid on 31 March 2026. Both are already past. DKK11.70 is an unchanged annual illustration, not a declared future total.Assuming unchanged future March finals and August interims gives one future cycle, DKK11.70, before 18 September 2027 and five cycles, DKK58.50, before 18 September 2031. At the explicit fixed ECB 16 October reference of DKK7.4748 per €1, that is €1.565259 and €7.826296 per share (about €1.57 and €7.83). Adding this assumed cash once to the weighted price endpoints gives +30.4% and +122.5% cumulative cash-inclusive base returns. These are gross before investor taxes and fees, without reinvestment and at constant illustrative FX. Future dividends and exchange rates can differ. Buybacks are separate.What could close—or widen—the gap?The thesis tests whether more patients and better factory utilization can outweigh net-price erosion. Drivers include oral and injectable reach, throughput and clinically supported indications. Frictions include rebates, competition, depreciation, ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません